Is complement good or bad for cancer patients? A new perspective on an old dilemma.
about
Comparison of tear protein levels in breast cancer patients and healthy controls using a de novo proteomic approachThe dual role of complement in cancer and its implication in anti-tumor therapyTag SNPs in complement receptor-1 contribute to the susceptibility to non-small cell lung cancerBlood peptidome-degradome profile of breast cancerReduced susceptibility to colitis-associated colon carcinogenesis in mice lacking plasma membrane-associated sialidaseComplement: a key system for immune surveillance and homeostasisCharacterization of a transgenic mouse model exhibiting spontaneous lung adenocarcinomas with a metastatic phenotype.C3d regulates immune checkpoint blockade and enhances antitumor immunity.Nanoparticles and the immune systemAn antimicrobial peptide regulates tumor-associated macrophage trafficking via the chemokine receptor CCR2, a model for tumorigenesis.Immunoglobulin G expression and its colocalization with complement proteins in papillary thyroid cancer.Opposing roles for complement component C5a in tumor progression and the tumor microenvironment.Complement anaphylatoxins as immune regulators in cancer.MicroRNA-centric measurement improves functional enrichment analysis of co-expressed and differentially expressed microRNA clustersPlasma clusterin as a candidate pre-diagnosis marker of colorectal cancer risk in the Florence cohort of the European Prospective Investigation into Cancer and Nutrition: a pilot study.Clinical predictive circulating peptides in rectal cancer patients treated with neoadjuvant chemoradiotherapy.Complement 5a Enhances Hepatic Metastases of Colon Cancer via Monocyte Chemoattractant Protein-1-mediated Inflammatory Cell Infiltration.Complement receptor 1 genetic variants contribute to the susceptibility to gastric cancer in chinese populationThe human complement inhibitor Sushi Domain-Containing Protein 4 (SUSD4) expression in tumor cells and infiltrating T cells is associated with better prognosis of breast cancer patients.A simple PCR-based method for the rapid genotyping of inherited fifth complement component (C5)-deficient mice.Paracrine and endocrine effects of adipose tissue on cancer development and progression.How do cytokines trigger genomic instability?Polymorphisms in complement system genes and risk of non-Hodgkin lymphomaProgress and Trends in Complement TherapeuticsComplement factor H polymorphism rs1061170 and the effect of cigarette smoking on the risk of lung cancer.C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation.Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic AdenovirusComplement in immune and inflammatory disorders: pathophysiological mechanismsNegative control of CSL gene transcription by stress/DNA damage response and p53.TUNABLE COMPLEMENT ACTIVATION BY PARTICLES WITH VARIABLE SIZE AND Fc DENSITYComplement factor H-derived short consensus repeat 18-20 enhanced complement-dependent cytotoxicity of ofatumumab on chronic lymphocytic leukemia cells.Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer.Complement inhibition in cancer therapy.Particle platforms for cancer immunotherapy.Rituximab: modes of action, remaining dispute and future perspective.A Normalization-Free and Nonparametric Method Sharpens Large-Scale Transcriptome Analysis and Reveals Common Gene Alteration Patterns in Cancers.The Ribosomal Protein S19 Suppresses Antitumor Immune Responses via the Complement C5a Receptor 1.Complement Membrane Attack and Tumorigenesis: A SYSTEMS BIOLOGY APPROACH.Regulation of complement-dependent cytotoxicity by TGF-β-induced epithelial-mesenchymal transition.Complement in Pancreatic Disease-Perpetrator or Savior?
P2860
Q24337286-8213CAA6-2824-46F2-A3DF-28D8642F1B01Q26738682-2E36000A-6017-4ECB-A6AD-C784A629F7DBQ28384476-987C96AE-4931-4CCA-B048-1A84C1BB9D20Q28475815-819DC322-8756-44DA-B737-28A124DF38EBQ28729113-C50DE3B8-988A-4D69-B36D-A1A602D3A596Q29615484-B4F65759-1DB1-491D-A71D-66E13054C821Q33574298-D67C678E-966A-4B5F-8DE4-30B853443048Q33631081-6AE0231F-D9CF-45D4-B681-FA3A0AD58E58Q33634320-3DC23E33-F9A6-4BED-9ADD-00A60B4D1294Q33900352-826A88F2-CDF9-4E5A-8885-0AFA97A56AC2Q34016093-ADD2ED51-C75A-49B2-833C-11DFC91436ECQ34295401-63495811-15F1-4ADA-AE8B-3D2107277CD2Q34414162-4772DBB3-667C-4AD9-9B11-0D0F24B2B0B2Q34529701-BFC4B24F-E3A0-4D3B-AA9B-24BE1FF7BA99Q35101910-E6D7A649-3E94-40E7-9049-4028537E3FA4Q35529674-B28ABA28-8D4F-4DD6-A0B7-720511774F57Q35536219-87F37082-BC3D-4A53-9557-D4119FEF4918Q35631618-DDD2B860-A893-4F5A-8109-1856B5A74682Q35813009-79887934-E550-424B-83AC-D2ABC02444D8Q35991991-5515AE98-50CF-4B34-B1C2-D221191A172EQ36014897-BE0C9191-39EA-4B33-ADFB-09FCF7321F39Q36057809-DDC655A9-D216-4999-9A56-E64846D63792Q36081383-A64B23D3-89BA-4A09-AD32-9F7C92A480E4Q36479278-53963E52-2177-4B3F-AFC7-371DA438C97DQ36516055-629BCD6E-2A12-448D-BBCD-DDBD7883E836Q36541076-19876043-01D9-4379-A4D7-276126F64FB8Q36582785-42338CC1-D487-4F42-A85F-D928667B1E1CQ36756850-02E16C17-3DBB-4D30-91F1-CABE9FDF9481Q37118737-6D7A7F3D-949A-45D3-87D8-A03F3DC7EA8BQ37137646-E20186F2-BD23-4902-A47D-0CE2D7D24D55Q37377923-2109BCF3-F9A2-4385-ABA6-E1CA5270CC79Q38068141-474841E2-E1C8-420D-8012-B55855C8FC91Q38109340-060AC00C-E3EC-48EA-AE94-083883DFBD4CQ38114060-9F2E7A9D-3952-4420-AC76-D4B3CF241047Q38294619-FE686488-A415-4240-A579-BCFCCDE2909EQ38616639-8876BAFF-DE75-4DE4-9703-FF54B30DBDC6Q38715342-61F7DBFA-5930-4D6A-8DD8-64DCF8A3E70BQ38768372-5C65C7E9-D14B-4A2C-B295-5B20B3DB642AQ38856280-DAEF3C48-53F6-4868-88C0-9E916998B672Q38988021-1A21D195-47A3-47AB-9661-83154F05CADE
P2860
Is complement good or bad for cancer patients? A new perspective on an old dilemma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Is complement good or bad for cancer patients? A new perspective on an old dilemma.
@en
Is complement good or bad for cancer patients? A new perspective on an old dilemma.
@nl
type
label
Is complement good or bad for cancer patients? A new perspective on an old dilemma.
@en
Is complement good or bad for cancer patients? A new perspective on an old dilemma.
@nl
prefLabel
Is complement good or bad for cancer patients? A new perspective on an old dilemma.
@en
Is complement good or bad for cancer patients? A new perspective on an old dilemma.
@nl
P2860
P356
P1433
P1476
Is complement good or bad for cancer patients? A new perspective on an old dilemma.
@en
P2093
Maciej M Markiewski
P2860
P304
P356
10.1016/J.IT.2009.04.002
P577
2009-05-08T00:00:00Z